Tactile Systems Technology (TCMD)
Tactile Systems Technology on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
2.8M
Short interest
settlement 2026-10-15
13.1
Days to cover
+3.3 days vs prior
53.4%
Short share of volume
2026-11-02
4
Fails to deliver
settlement 2026-10-13
Tue 16 Feb
Next earnings
estimated date
-$323K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TCMD is 2,829,763 shares, up 14,708 shares over the last month. Over the last 48 readings it ranged from 978,403 shares (15 November 2024) to 2,849,409 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 215K shares a day that is 13.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tcmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,829,763 | -0.7% | 215,393 | 13.14 |
| 2026-09-30 | 2,849,409 | +1.2% | 289,323 | 9.85 |
| 2026-09-15 | 2,815,055 | +7.8% | 270,258 | 10.42 |
| 2026-08-31 | 2,610,235 | +2.3% | 337,218 | 7.74 |
| 2026-08-14 | 2,551,437 | +8.5% | 427,149 | 5.97 |
| 2026-07-31 | 2,351,515 | -4.0% | 204,931 | 11.47 |
| 2026-07-15 | 2,449,398 | +0.2% | 232,591 | 10.53 |
| 2026-06-30 | 2,444,253 | +6.0% | 312,387 | 7.82 |
| 2026-06-15 | 2,305,560 | -2.4% | 211,795 | 10.89 |
| 2026-05-29 | 2,362,243 | +2.5% | 272,102 | 8.68 |
| 2026-05-15 | 2,305,387 | +26.2% | 486,381 | 4.74 |
| 2026-04-30 | 1,827,328 | +10.3% | 258,979 | 7.06 |
| 2026-04-15 | 1,656,036 | -1.0% | 232,800 | 7.11 |
| 2026-03-31 | 1,672,847 | -11.8% | 270,951 | 6.17 |
| 2026-03-13 | 1,897,308 | +8.5% | 267,718 | 7.09 |
| 2026-02-27 | 1,748,345 | -5.4% | 669,561 | 2.61 |
| 2026-02-13 | 1,848,548 | +1.0% | 229,643 | 8.05 |
| 2026-01-30 | 1,829,706 | -1.6% | 261,579 | 6.99 |
| 2026-01-15 | 1,858,682 | +5.0% | 368,452 | 5.04 |
| 2025-12-31 | 1,769,844 | -15.4% | 302,633 | 5.85 |
| 2025-12-15 | 2,092,362 | +12.7% | 394,635 | 5.30 |
| 2025-11-28 | 1,857,367 | +10.4% | 507,045 | 3.66 |
| 2025-11-14 | 1,682,581 | -8.4% | 1,024,147 | 1.64 |
| 2025-10-31 | 1,836,434 | -5.5% | 139,929 | 13.12 |
| 2025-10-15 | 1,943,127 | -0.9% | 161,208 | 12.05 |
| 2025-09-30 | 1,960,021 | -5.4% | 194,719 | 10.07 |
| 2025-09-15 | 2,071,561 | -2.6% | 206,039 | 10.05 |
| 2025-08-29 | 2,127,704 | -3.7% | 166,508 | 12.78 |
| 2025-08-15 | 2,208,738 | -3.4% | 338,494 | 6.53 |
| 2025-07-31 | 2,285,965 | -7.5% | 183,139 | 12.48 |
| 2025-07-15 | 2,472,061 | +2.8% | 177,055 | 13.96 |
| 2025-06-30 | 2,405,053 | -0.6% | 250,874 | 9.59 |
| 2025-06-13 | 2,420,498 | +6.8% | 259,945 | 9.31 |
| 2025-05-30 | 2,266,239 | -2.8% | 363,003 | 6.24 |
| 2025-05-15 | 2,330,288 | +7.4% | 552,244 | 4.22 |
| 2025-04-30 | 2,168,834 | -1.7% | 162,571 | 13.34 |
| 2025-04-15 | 2,207,246 | +3.1% | 267,760 | 8.24 |
| 2025-03-31 | 2,140,436 | +1.8% | 178,414 | 12.00 |
| 2025-03-14 | 2,102,529 | +1.7% | 266,292 | 7.90 |
| 2025-02-28 | 2,067,021 | -16.7% | 463,274 | 4.46 |
| 2025-02-14 | 2,481,236 | +73.5% | 306,711 | 8.09 |
| 2025-01-31 | 1,429,843 | -5.3% | 216,480 | 6.60 |
| 2025-01-15 | 1,510,157 | +7.5% | 195,397 | 7.73 |
| 2024-12-31 | 1,404,362 | +32.0% | 256,677 | 5.47 |
| 2024-12-13 | 1,064,090 | +6.0% | 240,686 | 4.42 |
| 2024-11-29 | 1,004,031 | +2.6% | 494,338 | 2.03 |
| 2024-11-15 | 978,403 | -22.3% | 385,834 | 2.54 |
| 2024-10-31 | 1,259,583 | -5.4% | 106,560 | 11.82 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of TCMD volume is 53.4%, down 36.3 points over the last five sessions. Over the last 30 readings it ranged from 37.6% (5 October 2026) to 89.7% (26 October 2026). The latest reading is 5.5 points below the 30-session average of 58.9%, on 76K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 41K | 76K | 53.4% | 0 |
| 2026-10-30 | 37K | 65K | 56.5% | 200 |
| 2026-10-29 | 32K | 51K | 63.7% | 0 |
| 2026-10-28 | 26K | 34K | 75.5% | 35 |
| 2026-10-27 | 24K | 57K | 41.1% | 0 |
| 2026-10-26 | 49K | 55K | 89.7% | 100 |
| 2026-10-23 | 35K | 45K | 79.5% | 0 |
| 2026-10-22 | 34K | 45K | 76.3% | 0 |
| 2026-10-21 | 45K | 64K | 71.4% | 9 |
| 2026-10-20 | 40K | 94K | 42.7% | 0 |
| 2026-10-19 | 32K | 58K | 55.3% | 343 |
| 2026-10-16 | 59K | 79K | 74.3% | 0 |
| 2026-10-15 | 45K | 78K | 58.2% | 3 |
| 2026-10-14 | 24K | 46K | 51.7% | 0 |
| 2026-10-13 | 28K | 50K | 56.4% | 0 |
| 2026-10-12 | 29K | 65K | 45.3% | 0 |
| 2026-10-09 | 25K | 50K | 49.5% | 0 |
| 2026-10-08 | 89K | 137K | 64.8% | 0 |
| 2026-10-07 | 42K | 79K | 53.8% | 0 |
| 2026-10-06 | 37K | 48K | 76.0% | 0 |
| 2026-10-05 | 26K | 70K | 37.6% | 0 |
| 2026-10-02 | 55K | 110K | 49.8% | 0 |
| 2026-10-01 | 24K | 44K | 53.9% | 1 |
| 2026-09-30 | 37K | 67K | 55.5% | 0 |
| 2026-09-29 | 26K | 70K | 37.8% | 0 |
| 2026-09-28 | 25K | 41K | 61.5% | 0 |
| 2026-09-25 | 44K | 82K | 54.0% | 0 |
| 2026-09-24 | 36K | 67K | 54.3% | 0 |
| 2026-09-23 | 44K | 55K | 80.2% | 0 |
| 2026-09-22 | 61K | 133K | 46.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in TCMD is 4 shares, down 2,190 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (25 September 2026) to 49,552 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 4 | $22.62 | $90 |
| 2026-10-05 | 2,194 | $22.10 | $48K |
| 2026-09-29 | 998 | $22.82 | $23K |
| 2026-09-25 | 1 | $22.89 | $23 |
| 2026-09-18 | 186 | $22.56 | $4K |
| 2026-09-14 | 48 | $22.40 | $1K |
| 2026-09-11 | 134 | $22.32 | $3K |
| 2026-09-09 | 925 | $21.73 | $20K |
| 2026-08-27 | 7 | $23.51 | $165 |
| 2026-08-21 | 7,140 | $23.43 | $167K |
| 2026-07-23 | 171 | $27.62 | $5K |
| 2026-07-01 | 49,552 | $29.78 | $1.5M |
| 2026-06-23 | 29 | $26.22 | $760 |
| 2026-06-18 | 306 | $25.83 | $8K |
| 2026-06-17 | 22 | $26.43 | $581 |
| 2026-06-12 | 609 | $26.35 | $16K |
| 2026-05-06 | 4 | $24.05 | $96 |
| 2026-05-05 | 7 | $22.43 | $157 |
| 2026-04-28 | 3,544 | $24.24 | $86K |
| 2026-04-15 | 5 | $25.06 | $125 |
| 2026-04-02 | 461 | $25.97 | $12K |
| 2026-04-01 | 457 | $26.13 | $12K |
| 2026-03-24 | 93 | $26.51 | $2K |
| 2026-03-23 | 418 | $26.10 | $11K |
| 2026-03-20 | 200 | $27.07 | $5K |
| 2026-03-19 | 23 | $27.03 | $622 |
| 2026-03-17 | 2 | $27.30 | $55 |
| 2026-03-16 | 5 | $26.93 | $135 |
| 2026-03-06 | 94 | $29.41 | $3K |
| 2026-02-27 | 2,831 | $29.91 | $85K |
Insider trades
SEC Form 4, newest first. JSONInsiders at TCMD reported 1 open-market sell worth $323K in the last 90 days and no open-market buys. Latest filing: Dodd Sheri Louise (Chief Executive Officer) on 2026-08-10.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Dodd Sheri Louise | Chief Executive Officer | Sell | 11K | $29.44 | $323K | 233K |
| 2026-05-11 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Sell | 5K | $24.49 | $113K | 130K |
| 2026-05-06 | Washington Boyd Vindell | Director | Grant | 7K | $0.00 | $0 | 42K |
| 2026-05-06 | Volkart Carmen B | Director | Grant | 7K | $0.00 | $0 | 44K |
| 2026-05-06 | Shafer David Brent | Director | Grant | 7K | $0.00 | $0 | 55K |
| 2026-05-06 | Pearson Andrea | Director | Grant | 7K | $0.00 | $0 | 7K |
| 2026-05-06 | King Laura G. | Director | Grant | 7K | $0.00 | $0 | 26K |
| 2026-05-06 | Huggenberger Raymond | Director | Grant | 7K | $0.00 | $0 | 63K |
| 2026-05-06 | BURKE WILLIAM W | Director | Grant | 7K | $0.00 | $0 | 55K |
| 2026-05-06 | Asbury Valerie L. | Director | Grant | 7K | $0.00 | $0 | 55K |
| 2026-03-09 | Pearson Andrea | Director | Grant | 852 | $0.00 | $0 | 852 |
| 2026-02-24 | Dodd Sheri Louise | Chief Executive Officer | Sell | 11K | $28.94 | $318K | 244K |
| 2026-02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 6K | $28.94 | $181K | 83K |
| 2026-02-24 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Sell | 8K | $28.94 | $223K | 135K |
| 2026-02-23 | Dodd Sheri Louise | Chief Executive Officer | Sell | 537 | $28.69 | $15K | 255K |
| 2026-02-23 | Dodd Sheri Louise | Chief Executive Officer | Sell | 15K | $28.28 | $416K | 255K |
| 2026-02-23 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 160 | $28.69 | $5K | 89K |
| 2026-02-23 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 4K | $28.28 | $121K | 89K |
| 2026-02-23 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Sell | 196 | $28.69 | $6K | 143K |
| 2026-02-23 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Sell | 5K | $28.28 | $151K | 143K |
| 2026-02-20 | Dodd Sheri Louise | Chief Executive Officer | Grant | 28K | $0.00 | $0 | 270K |
| 2026-02-20 | Dodd Sheri Louise | Chief Executive Officer | Grant | 20K | $0.00 | $0 | 242K |
| 2026-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 7K | $0.00 | $0 | 93K |
| 2026-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 4K | $0.00 | $0 | 86K |
| 2026-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 3K | $0.00 | $0 | 82K |
| 2026-02-20 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Grant | 16K | $0.00 | $0 | 148K |
| 2026-02-20 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Grant | 7K | $0.00 | $0 | 132K |
| 2026-02-20 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Grant | 4K | $0.00 | $0 | 126K |
| 2026-02-19 | Dodd Sheri Louise | Chief Executive Officer | Grant | 49K | $0.00 | $0 | 222K |
| 2026-02-19 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 6K | $0.00 | $0 | 79K |
| 2026-02-19 | Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Grant | 23K | $0.00 | $0 | 122K |
| 2026-01-02 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 5K | $28.85 | $148K | 72K |
| 2025-08-08 | Dodd Sheri Louise | Chief Executive Officer | Sell | 8K | $12.36 | $96K | 173K |
| 2025-05-12 | Birkemeyer Elaine M. | Chief Financial Officer | Sell | 3K | $9.94 | $29K | 99K |
| 2025-05-08 | BURKE WILLIAM W | Director | Sell | 3K | $9.67 | $32K | 49K |
| 2025-05-08 | Dodd Sheri Louise | Chief Executive Officer | Sell | 3K | $9.83 | $31K | 181K |
| 2025-05-07 | Washington Boyd Vindell | Director | Grant | 16K | $0.00 | $0 | 35K |
| 2025-05-07 | Volkart Carmen B | Director | Grant | 16K | $0.00 | $0 | 38K |
| 2025-05-07 | Shafer David Brent | Director | Grant | 16K | $0.00 | $0 | 49K |
| 2025-05-07 | King Laura G. | Director | Grant | 16K | $0.00 | $0 | 19K |
| 2025-05-07 | Huggenberger Raymond | Director | Grant | 16K | $0.00 | $0 | 56K |
| 2025-05-07 | Asbury Valerie L. | Director | Grant | 16K | $0.00 | $0 | 49K |
| 2025-05-07 | BURKE WILLIAM W | Director | Grant | 16K | $0.00 | $0 | 52K |
| 2025-03-11 | REUVERS DANIEL L. | Director | Gift | 68K | $0.00 | $0 | 146K |
| 2025-03-11 | REUVERS DANIEL L. | Director | Gift | 68K | $0.00 | $0 | 68K |
| 2025-02-25 | REUVERS DANIEL L. | Director | Sell | 28K | $14.18 | $402K | 215K |
| 2025-02-25 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 6K | $14.40 | $93K | 78K |
| 2025-02-25 | Birkemeyer Elaine M. | Chief Financial Officer | Sell | 2K | $14.51 | $30K | 102K |
| 2025-02-24 | Birkemeyer Elaine M. | Chief Financial Officer | Sell | 4K | $14.70 | $56K | 104K |
| 2025-02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 5K | $14.65 | $71K | 84K |
| 2025-02-24 | REUVERS DANIEL L. | Director | Sell | 11K | $14.55 | $159K | 243K |
| 2025-02-20 | Dodd Sheri Louise | Chief Executive Officer | Grant | 66K | $0.00 | $0 | 184K |
| 2025-02-20 | Dodd Sheri Louise | Chief Executive Officer | Grant | 20K | $0.00 | $0 | 119K |
| 2025-02-20 | King Laura G. | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2025-02-20 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 7K | $0.00 | $0 | 72K |
| 2025-02-20 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 3K | $0.00 | $0 | 65K |
| 2025-02-20 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 36K | $0.00 | $0 | 108K |
| 2025-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 4K | $0.00 | $0 | 72K |
| 2025-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 3K | $0.00 | $0 | 68K |
| 2025-02-20 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 17K | $0.00 | $0 | 89K |
| 2025-02-20 | REUVERS DANIEL L. | Director | Grant | 16K | $0.00 | $0 | 254K |
| 2024-08-12 | Ferstler Sherri Lee | Senior VP, Sales | Sell | 2K | $13.07 | $20K | 39K |
| 2024-08-07 | Dodd Sheri Louise | Chief Executive Officer | Grant | 65K | $0.00 | $0 | 99K |
| 2024-05-16 | Birkemeyer Elaine M. | Chief Financial Officer | Sell | 3K | $13.68 | $42K | 61K |
| 2024-05-08 | Washington Boyd Vindell | Director | Grant | 10K | $0.00 | $0 | 19K |
| 2024-05-08 | Volkart Carmen B | Director | Grant | 10K | $0.00 | $0 | 22K |
| 2024-05-08 | Shafer David Brent | Director | Grant | 10K | $0.00 | $0 | 33K |
| 2024-05-08 | Huggenberger Raymond | Director | Grant | 10K | $0.00 | $0 | 40K |
| 2024-05-08 | Dodd Sheri Louise | Director | Grant | 10K | $0.00 | $0 | 34K |
| 2024-05-08 | Asbury Valerie L. | Director | Grant | 10K | $0.00 | $0 | 33K |
| 2024-05-08 | BURKE WILLIAM W | Director | Sell | 3K | $14.06 | $35K | 25K |
| 2024-05-08 | BURKE WILLIAM W | Director | Grant | 10K | $0.00 | $0 | 36K |
| 2024-05-06 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 815 | $14.37 | $12K | 63K |
| 2024-02-29 | REUVERS DANIEL L. | President and CEO | Sell | 1K | $15.25 | $21K | 238K |
| 2024-02-29 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 243 | $15.25 | $4K | 63K |
| 2024-02-27 | REUVERS DANIEL L. | President and CEO | Sell | 5K | $15.60 | $73K | 239K |
| 2024-02-27 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 1K | $15.58 | $17K | 64K |
| 2024-02-26 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 2K | $15.91 | $32K | 64K |
| 2024-02-26 | REUVERS DANIEL L. | President and CEO | Sell | 6K | $15.81 | $99K | 244K |
| 2024-02-24 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 3K | $0.00 | $0 | 64K |
| 2024-02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 9K | $0.00 | $0 | 63K |
| 2024-02-24 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 3K | $0.00 | $0 | 66K |
| 2024-02-24 | REUVERS DANIEL L. | President and CEO | Grant | 45K | $0.00 | $0 | 237K |
| 2024-02-24 | REUVERS DANIEL L. | President and CEO | Grant | 13K | $0.00 | $0 | 250K |
| 2024-02-23 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 2K | $14.80 | $33K | 54K |
| 2024-02-23 | REUVERS DANIEL L. | President and CEO | Sell | 5K | $14.85 | $80K | 192K |
| 2024-02-21 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 32K | $0.00 | $0 | 61K |
| 2024-02-21 | Ferstler Sherri Lee | Senior VP, Sales | Grant | 22K | $0.00 | $0 | 40K |
| 2024-02-21 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Grant | 19K | $0.00 | $0 | 56K |
| 2024-02-21 | REUVERS DANIEL L. | President and CEO | Grant | 72K | $0.00 | $0 | 198K |
| 2023-11-08 | Washington Boyd Vindell | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2023-08-09 | Ferstler Sherri Lee | Senior VP, Sales | Grant | 19K | $0.00 | $0 | 19K |
| 2023-08-07 | REUVERS DANIEL L. | President and CEO | Sell | 1K | $20.53 | $22K | 126K |
| 2023-05-12 | BURKE WILLIAM W | Director | Sell | 4K | $21.86 | $96K | 28K |
| 2023-05-10 | Birkemeyer Elaine M. | Chief Financial Officer | Grant | 29K | $0.00 | $0 | 29K |
| 2023-05-08 | PAULS ERIC | Senior VP, Sales | Sell | 550 | $18.55 | $10K | 29K |
| 2023-05-08 | Burns Kristie | Sr. VP Mktg & Clinical Affairs | Sell | 786 | $18.65 | $15K | 37K |
| 2023-05-08 | Volkart Carmen B | Director | Grant | 8K | $0.00 | $0 | 11K |
| 2023-05-08 | Shafer David Brent | Director | Grant | 8K | $0.00 | $0 | 22K |
| 2023-05-08 | Huggenberger Raymond | Director | Grant | 8K | $0.00 | $0 | 30K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON10 Form 144 notices on file for TCMD worth $2.1M at the prices reported; 1 in the last 90 days worth $323K. Latest: Dodd Sheri Louise filed on 2026-08-10 to sell 10,978 shares ($323K) from 2026-08-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-10 | Dodd Sheri LouiseOfficer, Director | 11K | $323K | 0.048% | 2026-08-10 | Fidelity Brokerage Services LLC |
| 2026-05-11 | Birkemeyer Elaine M.Officer | 5K | $113K | 0.021% | 2026-05-11 | Fidelity Brokerage Services LLC |
| 2026-02-25 | Burns KristieOfficer | 4K | $114K | 0.018% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Dodd Sheri LouiseOfficer, Director | 11K | $318K | 0.049% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Burns KristieOfficer | 6K | $181K | 0.028% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Birkemeyer Elaine M.Officer | 8K | $223K | 0.034% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Dodd Sheri LouiseOfficer, Director | 15K | $431K | 0.068% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Burns KristieOfficer | 4K | $126K | 0.020% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Birkemeyer Elaine M.Officer | 6K | $156K | 0.025% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-01-02 | Burns KristieOfficer | 5K | $148K | 0.023% | 2026-01-02 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of TCMD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Cadian Capital Management, LP at 7.0% of the class (1,576,940 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 4 | Cadian Capital Management, LPinvestment adviser, partnership | 1.6M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Cadian Capital Management GP, LLCother entity, parent holding company | 1.6M | 7.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | ERIC BANNASCHindividual, parent holding company | 1.6M | 7.0% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 2 | Morgan Stanleyparent holding company, corporation | 830K | 3.7% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 2 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 783K | 3.5% | 2026-06-30 |
| 2026-03-27 | 13G/Ano. 7 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-12 | 13G/Ano. 2 | PARADIGM CAPITAL MANAGEMENT INC/NYinvestment adviser | 737K | 3.3% | 2025-12-31 |
| 2026-01-21 | 13G/Ano. 1 | Dimensional Fund Advisors LPinvestment adviser | 1.1M | 4.9% | 2025-12-31 |
13F holders
Tracked managers holding TCMD at their latest 13F. JSON5 of the 30 tracked managers held TCMD at their latest 13F, $25.0M in total at quarter-end prices. Renaissance Technologies is the largest at $14.1M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 474K | $14.1M | 0.02% | -37K |
| D. E. Shaw & Co. | 2026-06-30 | 184K | $5.5M | 0.00% | +30K |
| AQR Capital Management | 2026-06-30 | 80K | $2.4M | 0.00% | +7K |
| Citadel Advisors | 2026-06-30 | 56K | $1.7M | 0.00% | -9K |
| Two Sigma Investments | 2026-06-30 | 47K | $1.4M | 0.00% | -13K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Tactile Systems Technology in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Tactile Systems Technology (TCMD), SEC CIK 1027838, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-02.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-08-10.JSON and CSV
- Company record
- EDGAR filing index for CIK 1027838Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of TCMD is sold short?
2,829,763 shares were held short at the 2026-10-15 settlement, 13.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TCMD's daily short volume?
On 2026-11-02, 40,716 of the 76,238 TCMD shares reported to FINRA were sold short, 53.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TCMD have fails to deliver?
The SEC's latest file shows 4 TCMD shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are TCMD insiders buying or selling?
Insiders at TCMD reported 1 open-market sell worth $323K in the last 90 days and no open-market buys. Latest filing: Dodd Sheri Louise (Chief Executive Officer) on 2026-08-10.
Have TCMD insiders filed to sell?
10 Form 144 notices on file for TCMD worth $2.1M at the prices reported; 1 in the last 90 days worth $323K. Latest: Dodd Sheri Louise filed on 2026-08-10 to sell 10,978 shares ($323K) from 2026-08-10.
Who owns 5% or more of TCMD?
3 holders report 5% or more of TCMD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Cadian Capital Management, LP at 7.0% of the class (1,576,940 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own TCMD?
5 of the 30 tracked 13F managers held TCMD shares at their latest filing, $25.0M in all. The largest: Renaissance Technologies (474K shares, $14.1M), D. E. Shaw & Co. (184K shares, $5.5M), Cliff Asness's AQR Capital Management (80K shares, $2.4M), Ken Griffin's Citadel Advisors (56K shares, $1.7M), Two Sigma Investments (47K shares, $1.4M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.